Resource

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Singh, Sonal; Chang, Hsien-Yen; Richards, Thomas M; Weiner, Jonathan P; Clark, Jeanne M; Segal, Jodi B
JAMA internal medicine; 2013 Apr 8;173(7):534-9. PMID: 23440284
Department of Medicine, The Johns Hopkins University School of Medicine and Public Health, Baltimore,MD 21287, USA. sosingh@jhsph.edu
Category: 
General Reviews
Links: 
PubMed Article
Journal Article

Abstract

Acute pancreatitis has significant morbidity and mortality. Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)-based therapies, including a GLP-1 mimetic (exenatide) and a dipeptidyl peptidase 4 inhibitor (sitagliptin phosphate), may increase the risk of acute pancreatitis.